Could CAR T-cell therapies and T-cell engagers reshape the treatment landscape for kidney cancer?
@YuWeiChenMD explores early clinical findings, the potential for durable responses, and the challenges of translating these emerging approaches into meaningful benefits for patients with RCC.
#UromigosLive | #UromigosShorts
Although ICI-based combinations are a standard frontline therapy for #mRCC, most patients will progress. @drranamckay & @YuWeiChenMD discuss data from recent trials that may guide clinicians on treatment sequencing ➡️ https://t.co/zH22gtoPW4 #ASCODailyNews